




Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

1		<p>Hi, I'm Sarah Donahue, and I'm here to talk to you about adverse event management of oral therapies in hormone-positive/HER2-negative early-stage breast cancer. I am a nurse practitioner at the University of California in San Francisco.</p>
2		<p>Welcome.</p>
3		<p>So today I'll give you an overview of the oral oncolytic therapies in hormone-positive/HER2-negative early-stage breast cancer.</p> <p>We'll discuss the rationale for extended hormone therapy beyond the 5 years for certain patients.</p> <p>We'll discuss the tolerability and adverse event profile of endocrine therapy, including adverse events that most commonly contribute to adherence issues.</p> <p>We'll discuss the tolerability and adverse event profile of abemaciclib in early-stage breast cancer, and the adverse events associated with discontinuation that we've seen in metastatic breast cancer.</p> <p>We'll discuss safety considerations for patients receiving endocrine therapy, plus abemaciclib therapy.</p> <p>And we'll discuss management strategies for the different adverse events for the different therapies.</p>

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

<p>4</p>	<p>Ellie: A Patient With HR+/HER2- EBC</p> <ul style="list-style-type: none"> 60-year-old postmenopausal woman with suspicious calcifications in the left breast on screening and diagnostic mammogram with nothing seen on ultrasound Stereotactic-guided core biopsy: grade 2 IDC with grade 2 DCIS; ER positive >95% PR negative; HER2 negative (IHC 1-2+/FISH negative); Ki-67 30% MRI breast: irregularly shaped mass measuring 2.5 cm x 2.8 cm x 3.0 cm CC MRI/ultrasound: enlarged axillary lymph nodes PET/CT: no distant metastatic disease <p><small>CC: carcinoma-in-situ; DCIS: ductal carcinoma in-situ; ER: estrogen receptor; FISH: fluorescent in situ hybridization; IDC: invasive ductal carcinoma; MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography; PR: progesterone receptor.</small></p>	<p>So we're going to start with a case study. Ellie is a patient with hormone-positive/HER2-negative early-stage breast cancer. She's 60 years old. Postmenopausal. She had a suspicious calcification in the left breast on screening and diagnostic mammograms. And nothing was seen on her ultrasound.</p> <p>So she went and had a stereotactic-guided core biopsy that found grade 2 invasive ductal carcinoma with grade 2 DCIS. The invasive disease was estrogen receptor-positive, progesterone receptor-negative and HER2-negative. The Ki-67 was 30%.</p> <p>MRI of the breast showed an irregularly shaped mass measuring 2.5 by 2.8 by 3.0 cm. An MRI ultrasound also showed enlarged auxiliary lymph nodes.</p> <p>The PET/CT did not show any distant metastatic disease.</p>
<p>5</p>	<p>Systemic Adjuvant Therapy Options</p> <p>Several Systemic Adjuvant Therapy Options Are Now Available for Patients With HR+/HER2- EBC</p> <ul style="list-style-type: none"> Tamoxifen Aromatase Inhibitors Ovarian Suppression PARP Inhibition (gBRCAm) CDK4/6 Inhibition (in combination with ET) <p>Choice of adjuvant therapy depends on risk assessment, pre- vs postmenopausal status, AEs and tolerability of available therapies, and patient preference</p> <p><small>PARP: poly adenosine diphosphate ribose polymerase</small></p>	<p>So there are several systemic adjuvant therapy options for these patients with hormone-positive/HER2-negative early-stage breast cancer. We have our hormone therapies; tamoxifen, that's our oldest medication that's available. We have the newer aromatase inhibitors. And we also have ovarian suppression that we can give to patients to go along with their tamoxifen or aromatase inhibitor.</p> <p>We now have 2 additional therapies to give with the endocrine therapy—PARP inhibition and CDK4/6 inhibition.</p> <p>So the choice of adjuvant therapy depends on the risk assessment, pre- versus postmenopausal status of the patient, adverse event profile, and the tolerability of the available therapies for that individual patient, and the patient's preference, always.</p>




Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

<p>6</p>	<p>What is the Optimal Duration of Adjuvant Therapy in Patients With HR+/HER2- EBC?</p> <p>For decades, 5 years was the standard recommendation for adjuvant ET</p> <p>We now know that patients with EBC are at continued risk of relapse for up to 15 years after diagnosis, even after 5 years of adjuvant ET</p> <p>15</p> <p>Clinical trials have indicated that adjuvant ET taken for up to 10 years may further reduce recurrence and improve benefit compared with 5 years of ET</p> <p><small>Smith JE, et al. American Society of Clinical Oncology Educational Book. 2014;34(16):424-424. Pan H, et al. N Engl J Med. 2017;377:1836-1846.</small></p>	<p>So what is the optimal therapy for patients with early-stage breast cancer that are hormone-positive? For decades, it was always 5 years of adjuvant endocrine therapy. But that has changed. We now know that patients with early-stage breast cancer are at continued risk of relapse for up to 15 years after diagnosis, even after the 5 years of endocrine therapy.</p> <p>So how do we protect them longer? There have been clinical trials that have shown that adjuvant endocrine therapy taken for up to 10 years may further reduce recurrence and improve benefit compared with the 5-year benefit there is for some patients.</p>
<p>7</p>	<p>Majority of Recurrences in HR+/HER2- Breast Cancer Occur After 5 Years</p> <p>Risk of Distant Recurrence</p> <p>Risk of Death From Breast Cancer</p> <p><small>Pan H, et al. N Engl J Med. 2017;377:1836-1846. Reproduced for educational purposes only.</small></p>	<p>So who are these patients that need to be watched more closely and given more therapy? We know that patients with more nodes of their disease involved have higher risk of recurrence. And that risk of recurrence continues on out to 15+ years/20 years.</p> <p>So you see here that the node, in negative patients, their risk is much lower than the risk in patients with 4 to 9 positive nodes. So we need to really protect our higher-risk patients.</p>
<p>8</p>	<p>Efficacy of Tamoxifen in EBC</p> <p>Recurrence</p> <p>Mortality</p> <p><small>©. Reprinted with permission, with permission of ASCO. et al. Lancet. 2011;378:771-784. Reproduced for educational purposes only.</small></p>	<p>Tamoxifen has been shown to reduce the risk of recurrence of breast cancer by about 40%. You can see here, if you follow this line up, at 10 years, it's about 40%. And it's been shown to increase overall survival.</p>

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

<p>9</p>	 <p>ATLAS: 6,846 Women, ER+, 10 vs 5 Years of Tamoxifen</p> <p>Recurrence Years 5-9: RR 0.90 (0.76-1.02) Years 10+: RR 0.79 (0.62-0.99) All years: logrank p<0.002</p> <p>Mortality Years 5-9: RR 0.97 (0.76-1.18) Years 10+: RR 0.71 (0.56-0.91) All years: logrank p<0.01</p> <p>RR: risk ratio Davies C, et al. <i>Lancet</i>. 2013;381:805-816. Reproduced for educational purposes only.</p>	<p>The ATLAS trial looked to see if 10 years of tamoxifen would be better than 5 years of tamoxifen. And they did show a benefit across all women enrolled.</p>																																																															
<p>10</p>	 <p>Extended AI Therapy Trials</p> <table border="1"> <thead> <tr> <th>Trial</th> <th>N</th> <th>Median Follow-up</th> <th>Prior Treatment</th> <th>Randomization</th> <th>Node + Prior Chemotherapy</th> <th>DFS/Hazard Ratio</th> <th>P value</th> <th>Adherence, %</th> </tr> </thead> <tbody> <tr> <td>MA.17¹</td> <td>1918</td> <td>6.3 years</td> <td>TAM x 5 → AI x 5</td> <td>AI x 5 vs placebo</td> <td>46%</td> <td>59% vs 51% Hazard ratio 0.62 Benefit in CSC</td> <td>.01</td> <td>62.5</td> </tr> <tr> <td>NSABP B-42²</td> <td>3968</td> <td>6.9 years</td> <td>TAM → AI AI x 5</td> <td>AI x 5 vs placebo</td> <td>42%</td> <td>84.7% vs 81.3% Hazard ratio 0.85 (0.76-0.95)</td> <td>.046 NS</td> <td>62.5</td> </tr> <tr> <td>IDEAL³</td> <td>1824</td> <td>6.6 years</td> <td>TAM → AI = 5 TAM x 5 AI x 5</td> <td>AI x 5 vs AI x 2.5</td> <td>7%</td> <td>82% vs 83.4% Hazard ratio 0.92</td> <td>.49</td> <td>57.5</td> </tr> <tr> <td>DATA⁴</td> <td>1912</td> <td>6.5 years</td> <td>TAM x 2-3 TAM → AI = 5 TAM x 5 AI x 5</td> <td>AI x 5 vs AI x 5</td> <td>67%</td> <td>83.8% vs 79.4% Hazard ratio 0.92</td> <td>.07</td> <td>NR</td> </tr> <tr> <td>ABCSG 16⁵</td> <td>3468</td> <td>8.8 years</td> <td>TAM → AI = 5 TAM x 5 AI x 5</td> <td>AI x 5 vs AI x 5</td> <td>31%</td> <td>71% vs 70% Hazard ratio 1.007</td> <td>.925</td> <td>59.4</td> </tr> <tr> <td>AERAS⁶</td> <td>1697</td> <td>4.9 years</td> <td>TAM → AI = 5 AI x 5</td> <td>AI x 5 vs stop treatment</td> <td>20%</td> <td>91.9% vs 84.4% Hazard ratio 0.54 Ovarian: 97.2% vs 84.3%</td> <td>.0004 .007</td> <td>70</td> </tr> </tbody> </table> <p>AI: aromatase inhibitor; CSC: complete blood count; DFS: distant recurrence; NR: not reported; NS: non-significant; TAM: tamoxifen. ¹ Coates PJ, et al. <i>N Engl J Med</i>. 2010;363:2095-2103. ² Mamounas EP, et al. <i>Lancet Oncol</i>. 2010;11:2049-56. ³ Blake C, et al. <i>J Natl Cancer Inst</i>. 2016;110:1111-4. ⁴ Toppo V, et al. <i>Lancet Oncol</i>. 2017;18:1022-1031. ⁵ Coates PJ, et al. 2017 ASCO. Abstract 502.05. ⁶ Coates PJ, et al. <i>Cancer Res</i>. 2010;70:3993-4001.</p>	Trial	N	Median Follow-up	Prior Treatment	Randomization	Node + Prior Chemotherapy	DFS/Hazard Ratio	P value	Adherence, %	MA.17 ¹	1918	6.3 years	TAM x 5 → AI x 5	AI x 5 vs placebo	46%	59% vs 51% Hazard ratio 0.62 Benefit in CSC	.01	62.5	NSABP B-42 ²	3968	6.9 years	TAM → AI AI x 5	AI x 5 vs placebo	42%	84.7% vs 81.3% Hazard ratio 0.85 (0.76-0.95)	.046 NS	62.5	IDEAL ³	1824	6.6 years	TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 2.5	7%	82% vs 83.4% Hazard ratio 0.92	.49	57.5	DATA ⁴	1912	6.5 years	TAM x 2-3 TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 5	67%	83.8% vs 79.4% Hazard ratio 0.92	.07	NR	ABCSG 16 ⁵	3468	8.8 years	TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 5	31%	71% vs 70% Hazard ratio 1.007	.925	59.4	AERAS ⁶	1697	4.9 years	TAM → AI = 5 AI x 5	AI x 5 vs stop treatment	20%	91.9% vs 84.4% Hazard ratio 0.54 Ovarian: 97.2% vs 84.3%	.0004 .007	70	<p>So now how about the aromatase inhibitors? We know that aromatase inhibitors can reduce risk of recurrence by about 60% in women. Can we have patients take more aromatase inhibitor therapy for 10 years and reduce their risk further?</p> <p>So there's been several trials looking at that. They're all listed here. Two of those trials actually found a benefit in the patients they enrolled. And in those trials, some patients started on tamoxifen for a certain amount time, maybe when they were early stage or possibly when they were premenopausal. And then transitioned over to the aromatase inhibitor once they became postmenopausal; or they had ovarian suppression added in so that they could go on the aromatase inhibitor. A variety of situations occurred.</p> <p>But then for the last 5 years, they all went on aromatase inhibitors. And they found in the MA.17 and the AERAS trial that there was improved overall survival and reduced risk of recurrence.</p>
Trial	N	Median Follow-up	Prior Treatment	Randomization	Node + Prior Chemotherapy	DFS/Hazard Ratio	P value	Adherence, %																																																									
MA.17 ¹	1918	6.3 years	TAM x 5 → AI x 5	AI x 5 vs placebo	46%	59% vs 51% Hazard ratio 0.62 Benefit in CSC	.01	62.5																																																									
NSABP B-42 ²	3968	6.9 years	TAM → AI AI x 5	AI x 5 vs placebo	42%	84.7% vs 81.3% Hazard ratio 0.85 (0.76-0.95)	.046 NS	62.5																																																									
IDEAL ³	1824	6.6 years	TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 2.5	7%	82% vs 83.4% Hazard ratio 0.92	.49	57.5																																																									
DATA ⁴	1912	6.5 years	TAM x 2-3 TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 5	67%	83.8% vs 79.4% Hazard ratio 0.92	.07	NR																																																									
ABCSG 16 ⁵	3468	8.8 years	TAM → AI = 5 TAM x 5 AI x 5	AI x 5 vs AI x 5	31%	71% vs 70% Hazard ratio 1.007	.925	59.4																																																									
AERAS ⁶	1697	4.9 years	TAM → AI = 5 AI x 5	AI x 5 vs stop treatment	20%	91.9% vs 84.4% Hazard ratio 0.54 Ovarian: 97.2% vs 84.3%	.0004 .007	70																																																									
<p>11</p>	 <p>Clinical and Pathologic Factors Do Not Reliably Predict Benefit From Extended HT</p> <p>ATLAS Trial¹ NCIC CTG MA.17 Trial²</p> <p>Hormone Receptor Status Estrogen Positive (97%) Progesterone Positive (97%) Node Status Node Negative (28%) Node Positive (72%) Previous Chemotherapy No (20%) Yes (80%) Menopausal Status Pre- or Peri-menopausal (50%) Postmenopausal (50%) Duration of Tamoxifen ≥ 5 years (50%) < 5 years (50%)</p> <p>Hazard ratio (95% CI) 1.00 (0.44, 2.30) 1.00 (0.44, 2.30) 0.88 (0.45, 1.70) 0.42 (0.45, 0.38) 2.40 (0.40, 1.46) 0.84 (0.44, 0.93) 0.98 (0.40, 0.92) 0.71 (0.25, 0.98) 0.60 (0.11, 0.48) 0.84 (0.44, 0.94) 0.90 (0.41, 0.91)</p> <p>1. Davies C, et al. <i>Lancet</i>. 2013;381:805-816. 2. Coates PJ, et al. <i>J Natl Cancer Inst</i>. 2005;97:1262-1271. Reproduced for educational purposes only.</p>	<p>So were there patients in these trials, in the tamoxifen trial, the ATLAS trial, or the MA.17 trial, the aromatase inhibitor trial, that benefited more from having longer duration of endocrine therapy?</p> <p>And they found that it didn't matter if patients were younger or older, didn't matter if they were node-positive or node-</p>																																																															


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>negative. All patients benefited, even those that had had chemotherapy prior versus those that didn't. There really was no difference. Everybody benefited.</p> <p>The only group here, if you look, that didn't benefit were the people that were hormone receptor-negative. So that group. But that would make sense because they're not going to have those receptors to block.</p>
<p>12</p>		<p>The MA.17 trial, similarly, didn't have a difference in the benefit by node status, by age. NSABP did see some benefit in the B-42 trial. They also didn't have a difference.</p>
<p>13</p>	<ul style="list-style-type: none"> Benefit of extended HT has only been demonstrated in the clinical trials: <ul style="list-style-type: none"> TAM x 5 → TAM x 5 (aTTom, ATLAS) TAM x 5 → AI x 5 (MA.17, NSABP B-33, ABCSG 6a) Benefit of extending AI beyond 5 years is unclear No reliable way to predict who may benefit from ET Increased rates of fracture, new-onset osteoporosis, endometrial cancer Must individualize treatment considering underlying risk and short-/long-term side effects Need predictive biomarkers (Breast Cancer Index) 	<p>So the optimal duration of hormone therapy, if you took all of these trials together, wasn't demonstrated across the board. However, there were some things that we do know, that tamoxifen for 5 years, followed by tamoxifen for another 5 years is beneficial to most patients. And there were 3 trials that did show a benefit in the longer duration of aromatase inhibitor.</p> <p>So the benefit of extending aromatase inhibitors beyond 5 years is a little bit unclear. However, we do have some trials that show a benefit, so we do consider it longer duration in our higher-risk patients. However, what is the higher risk?</p> <p>There's really no reliable way to predict benefit from longer duration endocrine therapy. We do know that there's increased rates of new onset of osteoporosis, increased rates of endometrial cancer in certain patients on tamoxifen longer term.</p>



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>So we really need to think about each patient individually and discuss their risks, their short-term and long-term risks of continuing on therapy.</p> <p>We need predictive biomarkers so that we can determine who would benefit from longer-term endocrine therapy because it's a little bit unclear still. There's one available right now called the Breast Cancer Index. That is a test where they take tissue from the surgery, and we send it out for genomic testing at this company. These tests can predict benefit of endocrine therapy of beyond 5 years, as well as the risk of patients developing a late recurrence of their breast cancer. So there's sort of 2 outcomes with that test.</p> <p>There was a recent trial that did further validate the BCI, or Breast Cancer Index, so you may see that being used more often in practice.</p>
<p>14</p>	 <p>The Issue of Nonadherence to Adjuvant ET</p> <ul style="list-style-type: none"> • 23%-28% of patients prematurely discontinue HT (tamoxifen or AI)¹ • AEs are an important cause of nonadherence to adjuvant ET in patients with EBC²⁻⁴ • Oncology nurses can play a proactive role in promoting long-term treatment adherence by addressing treatment-related AEs²⁻⁴ <p>Additional strategies for promoting adherence to be covered in Activity 3.</p> <p><small>1. Chabowski RT, Geller ML. <i>Oncology</i>. 2006;7(1):1-6. 2. Hanna K, Mayden K. <i>J Adv Pract Oncol</i>. 2017;10(suppl 2):15-26. 3. Clancy C, et al. <i>Eur J Oncol Nurs</i>. 2020;44:101756. 4. Sorely CC, et al. <i>Breast Cancer Res Treat</i>. 2022;193:369-380.</small></p>	<p>Thinking about patients receiving endocrine therapy, I like to focus on just getting them through that first 5 years and then sort of approaching the next several years of hormone therapy, if I'm going to be recommending it at a later date.</p> <p>So we know that 23% to 28% of patients prematurely discontinue their hormone therapy, whether it be tamoxifen or an aromatase inhibitor. The biggest issue that I've found for nonadherence to these medications or discontinuation is the adverse events that are associated with endocrine therapies.</p> <p>So as nurses, I feel that our role is to ensure that patients stay on their hormone therapy. Like I said earlier, it reduces their risk of recurrence by between 40% and 60%, so it's incredibly important. And we can play a very large role in helping patients reduce that risk by</p>



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>treating those adverse events and discussing strategies to help them.</p> <p>We'll be discussing that more with Activity 3.</p>
<p>15</p>		<p>So what are the side effects of endocrine therapy?</p>
<p>16</p>	 <p>Ellie: Case Continued</p> <ul style="list-style-type: none"> ▪ Neoadjuvant paclitaxel weekly x 12 weeks followed by AC every 2 weeks x 4 cycles ▪ Lumpectomy and sentinel node biopsy: 5.5-cm (40% cellularity) + 0.4-cm (60% cellularity) residual grade 2 IDC, margins negative, 0/3 nodes. Associated 7 cm of intermediate to high nuclear grade DCIS, margins negative ▪ Breast radiation followed by letrozole + abemaciclib planned <p>How would you prepare Ellie for potential side effects associated with the ET component of her treatment regimen?</p> <p><small>AC: aromatase inhibitor and cyclophosphamide.</small></p>	<p>Let's go back to Ellie. She's been diagnosed with this hormone-positive/HER2-negative early-stage breast cancer. We decide that we're going to give her neoadjuvant chemotherapy. We give her paclitaxel weekly for 12 weeks. Then we follow that with AC every 2 weeks, times 4 cycles.</p> <p>She then goes on to have a lumpectomy and sentinel node biopsy. She's found to have 2 areas of residual disease—1 that's 5.5 cm and 40% cellularity, and the other is 0.4 cm and 60% cellularity. It's grade 2. The margins are negative.</p> <p>There were 3 sentinel nodes removed; none of them had cancer in them.</p> <p>She also had some DCIS in the breast tissue that was removed. The margins for that were negative.</p> <p>She then goes on to have breast radiation followed by letrozole and abemaciclib.</p> <p>How would you prepare Ellie for potential side effects associated with the endocrine therapy portion of her treatment?</p>



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

<p>17</p>	 <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="2">Patients, n (%)</th> <th rowspan="2">p value</th> </tr> <tr> <th>Anastrozole (n=3,092)</th> <th>Tamoxifen (n=3,094)</th> </tr> </thead> <tbody> <tr> <td>Hot flashes</td> <td>1,104 (35.7)</td> <td>1,264 (40.9)</td> <td>< .0001</td> </tr> <tr> <td>Arthralgias</td> <td>1,100 (35.6)</td> <td>911 (29.4)</td> <td>< .0001</td> </tr> <tr> <td>Vaginal bleeding</td> <td>167 (5.4)</td> <td>317 (10.2)</td> <td>< .0001</td> </tr> <tr> <td>Endometrial cancer*</td> <td>5 (0.2)</td> <td>17 (0.8)</td> <td>.02</td> </tr> <tr> <td>Fractures</td> <td>340 (11.0)</td> <td>237 (7.7)</td> <td>< .0001</td> </tr> <tr> <td> Hip</td> <td>37 (1.2)</td> <td>31 (1.0)</td> <td>.5</td> </tr> <tr> <td> Spine</td> <td>45 (1.5)</td> <td>27 (0.9)</td> <td>.03</td> </tr> <tr> <td> Wrist/Colles</td> <td>72 (2.3)</td> <td>63 (2.0)</td> <td>.4</td> </tr> <tr> <td> All other sites*</td> <td>220 (7.1)</td> <td>142 (4.6)</td> <td>< .0001</td> </tr> <tr> <td>Venous thromboembolic events</td> <td>87 (2.8)</td> <td>140 (4.5)</td> <td>.0004</td> </tr> </tbody> </table> <p><small>*n=2,223 for anastrozole, 2,232 for tamoxifen, excluding patients with hypercoagulable conditions, reported at any time. *Patients may have had 2+ fractures at different sites. Hossett A, et al. Lancet. 2005; 365:69-72.</small></p>		Patients, n (%)		p value	Anastrozole (n=3,092)	Tamoxifen (n=3,094)	Hot flashes	1,104 (35.7)	1,264 (40.9)	< .0001	Arthralgias	1,100 (35.6)	911 (29.4)	< .0001	Vaginal bleeding	167 (5.4)	317 (10.2)	< .0001	Endometrial cancer*	5 (0.2)	17 (0.8)	.02	Fractures	340 (11.0)	237 (7.7)	< .0001	Hip	37 (1.2)	31 (1.0)	.5	Spine	45 (1.5)	27 (0.9)	.03	Wrist/Colles	72 (2.3)	63 (2.0)	.4	All other sites*	220 (7.1)	142 (4.6)	< .0001	Venous thromboembolic events	87 (2.8)	140 (4.5)	.0004	<p>So what are the side effects?</p> <p>We know that both the aromatase inhibitors and tamoxifen can cause hot flashes.</p> <p>Joint aches and stiffness are seen with the aromatase inhibitors, but you can see that a little bit with the tamoxifen.</p> <p>Vaginal bleeding and endometrial cancer are really associated more with tamoxifen than the aromatase inhibitors. And we'll discuss that a little bit more later and what that means. But you see that these rates of endometrial cancer are actually quite low compared with the incidence of vaginal bleeding. So it doesn't always indicate endometrial cancer when a patient has vaginal bleeding.</p> <p>Aromatase inhibitors are associated with higher rates of osteoporosis. However, the fracture risk is not that much greater than with tamoxifen. It is increased, but not at a large amount.</p> <p>Venous thromboembolic events have been seen with tamoxifen as well.</p>
	Patients, n (%)		p value																																													
	Anastrozole (n=3,092)	Tamoxifen (n=3,094)																																														
Hot flashes	1,104 (35.7)	1,264 (40.9)	< .0001																																													
Arthralgias	1,100 (35.6)	911 (29.4)	< .0001																																													
Vaginal bleeding	167 (5.4)	317 (10.2)	< .0001																																													
Endometrial cancer*	5 (0.2)	17 (0.8)	.02																																													
Fractures	340 (11.0)	237 (7.7)	< .0001																																													
Hip	37 (1.2)	31 (1.0)	.5																																													
Spine	45 (1.5)	27 (0.9)	.03																																													
Wrist/Colles	72 (2.3)	63 (2.0)	.4																																													
All other sites*	220 (7.1)	142 (4.6)	< .0001																																													
Venous thromboembolic events	87 (2.8)	140 (4.5)	.0004																																													
<p>18</p>	 <p>Symptoms Reported At Least Once Between Months 3 and 36 With the Largest Relative Difference Between Trial Arms in the NSABP P-1 Trial</p> <table border="1"> <thead> <tr> <th>Symptom</th> <th>Placebo Arm Proportion, %</th> <th>Tamoxifen Arm Proportion, %</th> <th>Relative Risk (Tamoxifen/Placebo)</th> </tr> </thead> <tbody> <tr> <td>Vaginal discharge</td> <td>34.13</td> <td>54.77</td> <td>1.6</td> </tr> <tr> <td>Cold sweats</td> <td>14.77</td> <td>21.4</td> <td>1.45</td> </tr> <tr> <td>Genital itching</td> <td>38.29</td> <td>47.13</td> <td>1.23</td> </tr> <tr> <td>Night sweats</td> <td>54.92</td> <td>66.8</td> <td>1.22</td> </tr> <tr> <td>Hot flashes</td> <td>65.04</td> <td>77.66</td> <td>1.19</td> </tr> <tr> <td>Pain in intercourse</td> <td>24.13</td> <td>28.19</td> <td>1.17</td> </tr> <tr> <td>Bladder control (laugh)</td> <td>46.66</td> <td>52.51</td> <td>1.13</td> </tr> <tr> <td>Bladder control (other)</td> <td>47.79</td> <td>52.83</td> <td>1.11</td> </tr> <tr> <td>Weight loss</td> <td>41.97</td> <td>44.94</td> <td>1.07</td> </tr> <tr> <td>Vaginal bleeding</td> <td>21.26</td> <td>21.96</td> <td>1.03</td> </tr> </tbody> </table> <p><small>Day R, et al. J Clin Oncol. 1999;17:2699-2699.</small></p>	Symptom	Placebo Arm Proportion, %	Tamoxifen Arm Proportion, %	Relative Risk (Tamoxifen/Placebo)	Vaginal discharge	34.13	54.77	1.6	Cold sweats	14.77	21.4	1.45	Genital itching	38.29	47.13	1.23	Night sweats	54.92	66.8	1.22	Hot flashes	65.04	77.66	1.19	Pain in intercourse	24.13	28.19	1.17	Bladder control (laugh)	46.66	52.51	1.13	Bladder control (other)	47.79	52.83	1.11	Weight loss	41.97	44.94	1.07	Vaginal bleeding	21.26	21.96	1.03	<p>Tamoxifen was studied in a trial, one of the earlier trials, NSABP, where they compared tamoxifen with placebo in patients, and they found that there were higher rates of vaginal discharge. Usually it's like a clear/yellowish discharge.</p> <p>Higher rates of vasomotor symptoms like cold sweats, night sweats, and hot flashes.</p> <p>They also found that patients had a slightly increased experience with some incontinence, with stress incontinence and other types of incontinence.</p> <p>They found that weight loss was harder to achieve in patients on the tamoxifen arm, just by a small amount.</p>		
Symptom	Placebo Arm Proportion, %	Tamoxifen Arm Proportion, %	Relative Risk (Tamoxifen/Placebo)																																													
Vaginal discharge	34.13	54.77	1.6																																													
Cold sweats	14.77	21.4	1.45																																													
Genital itching	38.29	47.13	1.23																																													
Night sweats	54.92	66.8	1.22																																													
Hot flashes	65.04	77.66	1.19																																													
Pain in intercourse	24.13	28.19	1.17																																													
Bladder control (laugh)	46.66	52.51	1.13																																													
Bladder control (other)	47.79	52.83	1.11																																													
Weight loss	41.97	44.94	1.07																																													
Vaginal bleeding	21.26	21.96	1.03																																													




Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>And like I said earlier, there is this risk of vaginal bleeding, but it actually wasn't that much higher in the tamoxifen arm.</p> <p>And just to be clear, tamoxifen, if a patient is premenopausal and they get tamoxifen, they will have their periods. That is normal. It's the abnormal vaginal bleeding that we are discussing here.</p>																																																																																																																																		
<p>19</p>	 <p>Tamoxifen (cont)</p> <p>Risk of Endometrial Cancer, DVT, and PE in the NSABP-P1 and IBIS-1 Trials</p> <table border="1"> <thead> <tr> <th></th> <th></th> <th>Relative Risk (95% CI)</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Endometrial cancer</td> <td>Premenopausal</td> <td>1.19 (0.5-2.65)</td> <td>.6</td> </tr> <tr> <td>Postmenopausal</td> <td>3.32 (1.95-5.67)</td> <td>< .0001</td> </tr> <tr> <td>DVT — overall</td> <td>Premenopausal</td> <td>1.45 (1.09-3.07)</td> <td>.02</td> </tr> <tr> <td>DVT — active</td> <td>Premenopausal</td> <td>2.31 (1.23-4.31)</td> <td>.009</td> </tr> <tr> <td>DVT — inactive</td> <td>Premenopausal</td> <td>1.01 (0.38-2.67)</td> <td>.9</td> </tr> <tr> <td rowspan="2">PE</td> <td>Premenopausal</td> <td>1.16 (0.55-2.43)</td> <td>.6</td> </tr> <tr> <td>Postmenopausal</td> <td>1.46 (0.94-2.29)</td> <td>.1</td> </tr> </tbody> </table> <p><small>DVT: deep vein thrombosis; PE: pulmonary embolism. Source: Pritchard et al. Cancer Treat Res. 2012;165:15-20.</small></p>			Relative Risk (95% CI)	p value	Endometrial cancer	Premenopausal	1.19 (0.5-2.65)	.6	Postmenopausal	3.32 (1.95-5.67)	< .0001	DVT — overall	Premenopausal	1.45 (1.09-3.07)	.02	DVT — active	Premenopausal	2.31 (1.23-4.31)	.009	DVT — inactive	Premenopausal	1.01 (0.38-2.67)	.9	PE	Premenopausal	1.16 (0.55-2.43)	.6	Postmenopausal	1.46 (0.94-2.29)	.1	<p>Endometrial cancer in this trial was noted and found, but it was seen only in the postmenopausal patients. That is the group that was driving the endometrial cancer risk.</p> <p>Deep vein thrombosis was seen in patients on tamoxifen. However, they found that if the patients discontinued the tamoxifen, that risk went away. So those on active therapy with tamoxifen had this increased risk, but once they stopped the medication—they became inactive on the tamoxifen—their risk reduced.</p> <p>And pulmonary embolism was seen in both groups, the pre- and the postmenopausal patients. Low rates, but certainly significant.</p>																																																																																																				
		Relative Risk (95% CI)	p value																																																																																																																																	
Endometrial cancer	Premenopausal	1.19 (0.5-2.65)	.6																																																																																																																																	
	Postmenopausal	3.32 (1.95-5.67)	< .0001																																																																																																																																	
DVT — overall	Premenopausal	1.45 (1.09-3.07)	.02																																																																																																																																	
DVT — active	Premenopausal	2.31 (1.23-4.31)	.009																																																																																																																																	
DVT — inactive	Premenopausal	1.01 (0.38-2.67)	.9																																																																																																																																	
PE	Premenopausal	1.16 (0.55-2.43)	.6																																																																																																																																	
	Postmenopausal	1.46 (0.94-2.29)	.1																																																																																																																																	
<p>20</p>	 <p>Aromatase Inhibitors</p> <p>Acute Toxicities Reported by Patients in NCIC CTG MA.17</p> <table border="1"> <thead> <tr> <th rowspan="2">Toxicity</th> <th colspan="5">Letrozole (n=2,572)</th> <th colspan="5">Placebo (n=2,577)</th> <th rowspan="2">p value</th> </tr> <tr> <th>Grade 1</th> <th>Grade 2</th> <th>Grade 3</th> <th>Grade 4</th> <th>Total, n (%)</th> <th>Grade 1</th> <th>Grade 2</th> <th>Grade 3</th> <th>Grade 4</th> <th>Total, n (%)</th> </tr> </thead> <tbody> <tr> <td>Edema</td> <td>470</td> <td>96</td> <td>5</td> <td></td> <td>571 (22)</td> <td>428</td> <td>110</td> <td>3</td> <td>1</td> <td>542 (21)</td> <td>.31</td> </tr> <tr> <td>Hypertension</td> <td>54</td> <td>21</td> <td>55</td> <td></td> <td>130 (5)</td> <td>48</td> <td>13</td> <td>68</td> <td></td> <td>129 (5)</td> <td>.94</td> </tr> <tr> <td>Hot flashes/flushes</td> <td>823</td> <td>661</td> <td>2</td> <td></td> <td>1,486 (58)</td> <td>782</td> <td>601</td> <td></td> <td></td> <td>1,383 (54)</td> <td>.003</td> </tr> <tr> <td>Fatigue</td> <td>801</td> <td>183</td> <td>14</td> <td>1</td> <td>999 (39)</td> <td>795</td> <td>195</td> <td>7</td> <td>1</td> <td>998 (39)</td> <td>.95</td> </tr> <tr> <td>Anorexia</td> <td>115</td> <td>26</td> <td>1</td> <td></td> <td>142 (6)</td> <td>87</td> <td>19</td> <td>3</td> <td>1</td> <td>110 (4)</td> <td>.039</td> </tr> <tr> <td>Constipation</td> <td>297</td> <td>60</td> <td>6</td> <td></td> <td>363 (14)</td> <td>313</td> <td>66</td> <td>3</td> <td></td> <td>382 (15)</td> <td>.48</td> </tr> <tr> <td>Diarrhea</td> <td>125</td> <td>29</td> <td>14</td> <td></td> <td>168 (7)</td> <td>140</td> <td>26</td> <td>10</td> <td></td> <td>176 (7)</td> <td>.69</td> </tr> <tr> <td>Nausea</td> <td>267</td> <td>35</td> <td>6</td> <td></td> <td>308 (12)</td> <td>267</td> <td>38</td> <td>9</td> <td></td> <td>314 (12)</td> <td>.83</td> </tr> <tr> <td>Hypercholesterolemia</td> <td>379</td> <td>37</td> <td>2</td> <td></td> <td>418 (16)</td> <td>357</td> <td>48</td> <td>6</td> <td>1</td> <td>411 (16)</td> <td>.79</td> </tr> </tbody> </table> <p><small>Source: PE, et al. J Natl Cancer Inst. 2005;97:1262-1271.</small></p>	Toxicity	Letrozole (n=2,572)					Placebo (n=2,577)					p value	Grade 1	Grade 2	Grade 3	Grade 4	Total, n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Total, n (%)	Edema	470	96	5		571 (22)	428	110	3	1	542 (21)	.31	Hypertension	54	21	55		130 (5)	48	13	68		129 (5)	.94	Hot flashes/flushes	823	661	2		1,486 (58)	782	601			1,383 (54)	.003	Fatigue	801	183	14	1	999 (39)	795	195	7	1	998 (39)	.95	Anorexia	115	26	1		142 (6)	87	19	3	1	110 (4)	.039	Constipation	297	60	6		363 (14)	313	66	3		382 (15)	.48	Diarrhea	125	29	14		168 (7)	140	26	10		176 (7)	.69	Nausea	267	35	6		308 (12)	267	38	9		314 (12)	.83	Hypercholesterolemia	379	37	2		418 (16)	357	48	6	1	411 (16)	.79	<p>Acute toxicities in patients on the MA.17 trial with aromatase inhibitors were seen.</p> <p>Hot flashes were more likely to be seen in patients on the letrozole arm.</p> <p>And there was a slight trend toward issues with weight loss. I actually have not seen that in practice, so I find that to be really interesting.</p> <p>Patients will often ask you about hypercholesterolemia while on the aromatase inhibitors, but really there was no difference in the placebo versus the aromatase inhibitor arm of this trial.</p>
Toxicity	Letrozole (n=2,572)					Placebo (n=2,577)					p value																																																																																																																									
	Grade 1	Grade 2	Grade 3	Grade 4	Total, n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Total, n (%)																																																																																																																										
Edema	470	96	5		571 (22)	428	110	3	1	542 (21)	.31																																																																																																																									
Hypertension	54	21	55		130 (5)	48	13	68		129 (5)	.94																																																																																																																									
Hot flashes/flushes	823	661	2		1,486 (58)	782	601			1,383 (54)	.003																																																																																																																									
Fatigue	801	183	14	1	999 (39)	795	195	7	1	998 (39)	.95																																																																																																																									
Anorexia	115	26	1		142 (6)	87	19	3	1	110 (4)	.039																																																																																																																									
Constipation	297	60	6		363 (14)	313	66	3		382 (15)	.48																																																																																																																									
Diarrhea	125	29	14		168 (7)	140	26	10		176 (7)	.69																																																																																																																									
Nausea	267	35	6		308 (12)	267	38	9		314 (12)	.83																																																																																																																									
Hypercholesterolemia	379	37	2		418 (16)	357	48	6	1	411 (16)	.79																																																																																																																									

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>Usually we don't have patients having GI toxicities, such as nausea, diarrhea, and constipation.</p> <p>I have not had issues with patients having hypertension, and nor do they in this trial.</p>																																																																																																																			
21	 <p>Aromatase Inhibitors (cont)</p> <p>Acute Toxicities Reported by Patients in NCIC CTG MA.17</p> <table border="1"> <thead> <tr> <th rowspan="2">Toxicity</th> <th colspan="4">Letrozole (n=2,472)</th> <th rowspan="2">Total, n (%)</th> <th colspan="4">Placebo (n=2,877)</th> <th rowspan="2">p value</th> </tr> <tr> <th>Grade 1</th> <th>Grade 2</th> <th>Grade 3</th> <th>Grade 4</th> <th>Grade 1</th> <th>Grade 2</th> <th>Grade 3</th> <th>Grade 4</th> </tr> </thead> <tbody> <tr> <td>Dizziness</td> <td>386</td> <td>99</td> <td>13</td> <td></td> <td>498 (18)</td> <td>383</td> <td>51</td> <td>6</td> <td>1</td> <td>441 (17)</td> <td>.53</td> </tr> <tr> <td>Insomnia</td> <td>119</td> <td>45</td> <td>2</td> <td></td> <td>166 (6)</td> <td>153</td> <td>35</td> <td>2</td> <td></td> <td>190 (6)</td> <td>.06</td> </tr> <tr> <td>Depression</td> <td>85</td> <td>42</td> <td>14</td> <td>2</td> <td>143 (5)</td> <td>74</td> <td>49</td> <td>7</td> <td>1</td> <td>131 (5)</td> <td>.45</td> </tr> <tr> <td>Headache</td> <td>546</td> <td>138</td> <td>22</td> <td></td> <td>706 (27)</td> <td>519</td> <td>140</td> <td>25</td> <td>1</td> <td>685 (27)</td> <td>.49</td> </tr> <tr> <td>Arthralgia</td> <td>381</td> <td>246</td> <td>25</td> <td></td> <td>651 (26)</td> <td>338</td> <td>172</td> <td>22</td> <td></td> <td>532 (21)</td> <td><.001</td> </tr> <tr> <td>Myalgia</td> <td>241</td> <td>121</td> <td>18</td> <td></td> <td>380 (15)</td> <td>211</td> <td>88</td> <td>11</td> <td></td> <td>310 (12)</td> <td>.004</td> </tr> <tr> <td>Alopecia</td> <td>114</td> <td>12</td> <td></td> <td></td> <td>126 (5)</td> <td>84</td> <td>5</td> <td></td> <td></td> <td>89 (3)</td> <td>.01</td> </tr> <tr> <td>Vaginal dryness</td> <td>75</td> <td>72</td> <td></td> <td></td> <td>147 (6)</td> <td>60</td> <td>69</td> <td></td> <td></td> <td>129 (5)</td> <td>.26</td> </tr> </tbody> </table> <p><small>Goos PE, et al. J Natl Cancer Inst. 2005;97:1302-1071.</small></p>	Toxicity	Letrozole (n=2,472)				Total, n (%)	Placebo (n=2,877)				p value	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4	Dizziness	386	99	13		498 (18)	383	51	6	1	441 (17)	.53	Insomnia	119	45	2		166 (6)	153	35	2		190 (6)	.06	Depression	85	42	14	2	143 (5)	74	49	7	1	131 (5)	.45	Headache	546	138	22		706 (27)	519	140	25	1	685 (27)	.49	Arthralgia	381	246	25		651 (26)	338	172	22		532 (21)	<.001	Myalgia	241	121	18		380 (15)	211	88	11		310 (12)	.004	Alopecia	114	12			126 (5)	84	5			89 (3)	.01	Vaginal dryness	75	72			147 (6)	60	69			129 (5)	.26	<p>In addition, insomnia was seen more in the patients that received the aromatase inhibitor. And the joint aches and stiffness, as we discussed earlier, more so in the patients receiving the aromatase inhibitor.</p> <p>Hair thinning was also more likely to occur in the patients on the aromatase inhibitor. And it's not like a full loss of hair; it's really just thinning. And it can settle down after about 1 year.</p> <p>All of these symptoms, I've found, can settle down after about 1 year. The beginning is usually the hardest part.</p>
Toxicity	Letrozole (n=2,472)				Total, n (%)	Placebo (n=2,877)				p value																																																																																																											
	Grade 1	Grade 2	Grade 3	Grade 4		Grade 1	Grade 2	Grade 3	Grade 4																																																																																																												
Dizziness	386	99	13		498 (18)	383	51	6	1	441 (17)	.53																																																																																																										
Insomnia	119	45	2		166 (6)	153	35	2		190 (6)	.06																																																																																																										
Depression	85	42	14	2	143 (5)	74	49	7	1	131 (5)	.45																																																																																																										
Headache	546	138	22		706 (27)	519	140	25	1	685 (27)	.49																																																																																																										
Arthralgia	381	246	25		651 (26)	338	172	22		532 (21)	<.001																																																																																																										
Myalgia	241	121	18		380 (15)	211	88	11		310 (12)	.004																																																																																																										
Alopecia	114	12			126 (5)	84	5			89 (3)	.01																																																																																																										
Vaginal dryness	75	72			147 (6)	60	69			129 (5)	.26																																																																																																										
22	 <p>Aromatase Inhibitors (cont)</p> <p>Bone and Cardiovascular Toxicities, AEs, and Intercurrent Illnesses in Patients in NCIC CTG MA.17</p> <table border="1"> <thead> <tr> <th>Event</th> <th>Letrozole, n (%)</th> <th>Placebo, n (%)</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>All patients</td> <td>2,572</td> <td>2,877</td> <td></td> </tr> <tr> <td rowspan="3">Clinical bone fractures</td> <td>Yes</td> <td>137 (5.3)</td> <td>119 (4.6)</td> <td>.25</td> </tr> <tr> <td>No</td> <td>2,434 (94.2)</td> <td>2,446 (84.9)</td> <td></td> </tr> <tr> <td>Missing</td> <td>11 (0.4)</td> <td>12 (0.5)</td> <td></td> </tr> <tr> <td rowspan="3">New osteoporosis</td> <td>Yes</td> <td>209 (8.1)</td> <td>155 (5.0)</td> <td>.003</td> </tr> <tr> <td>No</td> <td>2,362 (91.4)</td> <td>2,410 (83.5)</td> <td></td> </tr> <tr> <td>Missing</td> <td>11 (0.4)</td> <td>12 (0.5)</td> <td></td> </tr> <tr> <td rowspan="3">Cardiovascular disease</td> <td>Yes</td> <td>149 (5.8)</td> <td>144 (5.0)</td> <td>.76</td> </tr> <tr> <td>No</td> <td>2,422 (93.8)</td> <td>2,421 (83.9)</td> <td></td> </tr> <tr> <td>Missing</td> <td>11 (0.4)</td> <td>12 (0.5)</td> <td></td> </tr> </tbody> </table> <p><small>Goos PE, et al. J Natl Cancer Inst. 2005;97:1302-1071.</small></p>	Event	Letrozole, n (%)	Placebo, n (%)	p value	All patients	2,572	2,877		Clinical bone fractures	Yes	137 (5.3)	119 (4.6)	.25	No	2,434 (94.2)	2,446 (84.9)		Missing	11 (0.4)	12 (0.5)		New osteoporosis	Yes	209 (8.1)	155 (5.0)	.003	No	2,362 (91.4)	2,410 (83.5)		Missing	11 (0.4)	12 (0.5)		Cardiovascular disease	Yes	149 (5.8)	144 (5.0)	.76	No	2,422 (93.8)	2,421 (83.9)		Missing	11 (0.4)	12 (0.5)		<p>As you know, aromatase inhibitors can lead to decreased bone density. They did not see a difference in patients experiencing fracture in the placebo versus the aromatase inhibitor arm. But they did see a higher incidence of osteoporosis, or the development of new osteoporosis in the aromatase inhibitor arm.</p> <p>And there was no difference in cardiovascular disease.</p>																																																																				
Event	Letrozole, n (%)	Placebo, n (%)	p value																																																																																																																		
All patients	2,572	2,877																																																																																																																			
Clinical bone fractures	Yes	137 (5.3)	119 (4.6)	.25																																																																																																																	
	No	2,434 (94.2)	2,446 (84.9)																																																																																																																		
	Missing	11 (0.4)	12 (0.5)																																																																																																																		
New osteoporosis	Yes	209 (8.1)	155 (5.0)	.003																																																																																																																	
	No	2,362 (91.4)	2,410 (83.5)																																																																																																																		
	Missing	11 (0.4)	12 (0.5)																																																																																																																		
Cardiovascular disease	Yes	149 (5.8)	144 (5.0)	.76																																																																																																																	
	No	2,422 (93.8)	2,421 (83.9)																																																																																																																		
	Missing	11 (0.4)	12 (0.5)																																																																																																																		
23	 <p>Hot Flashes: Interventions</p> <table border="1"> <thead> <tr> <th>Nonpharmacologic</th> <th>Pharmacologic^a</th> </tr> </thead> <tbody> <tr> <td>Cool layers, light blanket at night, cooler air</td> <td>Gabapentin: starting dose, 300 mg daily at bedtime. Increase every 3-5 days by 300 mg (max 1,200 mg daily at bedtime). Can cause somnolence/sedation and dizziness. Best to take every night rather than as needed.¹</td> </tr> <tr> <td>Acupuncture</td> <td>Venlafaxine-XR: starting dose: 37.5 mg daily. Increase if needed after 2-4 weeks to 75 mg (max dose 225 mg). Can cause dizziness, somnolence, and nausea in the first weeks. Must take every day without breaks.²</td> </tr> <tr> <td>Diet changes—avoid triggers</td> <td>Citalopram: starting dose: 10 mg daily at bedtime. Increase if needed after 2-4 weeks to 20 mg (max dose 40 mg). Category B interaction with tamoxifen due to QT prolongation. No interaction with AIs.³</td> </tr> <tr> <td>Reduce anxiety and stress</td> <td>Oxybutynin: starting dose: 2.5 mg twice daily. Increase if needed after 2 weeks (max dose 5 mg twice daily). Can cause anticholinergic side effects.⁴</td> </tr> <tr> <td>Take HT at different time of day</td> <td></td> </tr> </tbody> </table> <p><small>^a Hot US Food and Drug Administration approved for hot flashes. ¹ Cancer.gov. https://www.cancer.gov/types/breast/meds/07/gabapentin. Accessed 2/11/2020. ² Cancer.gov. https://www.cancer.gov/types/breast/meds/07/venlafaxine. Accessed 2/11/2020. ³ Cancer.gov. https://www.cancer.gov/types/breast/meds/07/citalopram. Accessed 2/11/2020. ⁴ Cancer.gov. https://www.cancer.gov/types/breast/meds/07/oxybutynin. Accessed 2/11/2020.</small></p>	Nonpharmacologic	Pharmacologic ^a	Cool layers, light blanket at night, cooler air	Gabapentin: starting dose, 300 mg daily at bedtime. Increase every 3-5 days by 300 mg (max 1,200 mg daily at bedtime). Can cause somnolence/sedation and dizziness. Best to take every night rather than as needed. ¹	Acupuncture	Venlafaxine-XR: starting dose: 37.5 mg daily. Increase if needed after 2-4 weeks to 75 mg (max dose 225 mg). Can cause dizziness, somnolence, and nausea in the first weeks. Must take every day without breaks. ²	Diet changes—avoid triggers	Citalopram: starting dose: 10 mg daily at bedtime. Increase if needed after 2-4 weeks to 20 mg (max dose 40 mg). Category B interaction with tamoxifen due to QT prolongation. No interaction with AIs. ³	Reduce anxiety and stress	Oxybutynin: starting dose: 2.5 mg twice daily. Increase if needed after 2 weeks (max dose 5 mg twice daily). Can cause anticholinergic side effects. ⁴	Take HT at different time of day		<p>So how do we manage these side effects?</p> <p>For hot flashes, there's a lot of nonpharmacologic things that we can do to help patients, and I always start there when I'm treating patients for symptoms. Just because it doesn't add a new medication that could have other side effects. And patients often prefer to have something that's not a medication-based treatment.</p>																																																																																																							
Nonpharmacologic	Pharmacologic ^a																																																																																																																				
Cool layers, light blanket at night, cooler air	Gabapentin: starting dose, 300 mg daily at bedtime. Increase every 3-5 days by 300 mg (max 1,200 mg daily at bedtime). Can cause somnolence/sedation and dizziness. Best to take every night rather than as needed. ¹																																																																																																																				
Acupuncture	Venlafaxine-XR: starting dose: 37.5 mg daily. Increase if needed after 2-4 weeks to 75 mg (max dose 225 mg). Can cause dizziness, somnolence, and nausea in the first weeks. Must take every day without breaks. ²																																																																																																																				
Diet changes—avoid triggers	Citalopram: starting dose: 10 mg daily at bedtime. Increase if needed after 2-4 weeks to 20 mg (max dose 40 mg). Category B interaction with tamoxifen due to QT prolongation. No interaction with AIs. ³																																																																																																																				
Reduce anxiety and stress	Oxybutynin: starting dose: 2.5 mg twice daily. Increase if needed after 2 weeks (max dose 5 mg twice daily). Can cause anticholinergic side effects. ⁴																																																																																																																				
Take HT at different time of day																																																																																																																					

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>So I tell them cool layers, like blankets at night; cooler air, like A/C if they have; windows open; fan on.</p> <p>Acupuncture actually has been shown to reduce hot flashes.</p> <p>Diet changes, like avoiding triggers. I have patients that tell me all sorts of things about what triggers them—wine, coffee, spicy foods. I have a patient that tells me that sugar really gets her to have a hot flash pretty quickly. So she avoids that, which is fine by me.</p> <p>Stress and anxiety can increase hot flashes, so really working on methods of reducing stress and anxiety, meditating—those things can really help.</p> <p>And then, taking the hormone therapy at a different time of day. So some patients might notice the first 5 or 6 hours after they take their aromatase inhibitor or their tamoxifen, they're having their hot flashes. So I have them, instead of taking it in the morning, take it at night. But if it's making it so they can't sleep through it, then I tell them to take it in the morning. So it's such a simple thing; just moving around when they take it so when they do have their hot flashes, it's a little bit more tolerable at that time of day.</p> <p>We have all these medications—I'm just going to pull them up all here—that can reduce hot flashes. These first 3 have been shown to reduce hot flashes by about 50% in trials:</p> <p>Gabapentin we start at 300 mg at bedtime. It is definitely really good at helping people get sleepy at night, as well as reducing the intensity and the frequency of the hot flashes.</p>
--	--	---

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence


Adverse Event Management of Oral Therapies in HR+/HER2- EBC

	<p>I do allow them to increase the dose every few days. It really takes a few days to know what is happening at night. So I don't want them to increase it too quickly. It can make them groggy in the morning and feel dizzy. So I definitely have them move it up before bedtime. Like if it's 9 PM, take it at 7 PM. That can help.</p> <p>Sometimes I have to start patients on the 100-mg dose because 300 mg is too much. I start at 300 mg in most patients though because that's the dose that I find to be actually effective; 100 mg can be kind of like a drop in the bucket, it doesn't help much.</p> <p>And it's best to take it every night rather than as needed. It really works better. But you don't have to take it every night. It's not habit-forming. It doesn't cause negative side effects if it's not taken every night.</p> <p>Venlafaxine is an SNRI that patients can take to reduce their hot flashes. For anxiety and depression, the starting dose is 75 mg, but for hot flashes we can start them off at 37.5 mg. They can take that morning or night. We increase it after about 2 to 4 weeks, depending on how they're doing. We double the dose to 75 mg. The maximum dose is 225 mg a day.</p> <p>This medication, the side effects are generally seen in the first week, and that's dizziness, somnolence, and nausea. But then they get used to it and that gets better. So I always tell patients, try to stay on the medication for at least 2 weeks before stopping and deciding that you don't tolerate it, because those side effects do go away most of the time.</p> <p>This medication needs to be taken every day without breaks. If you start and stop,</p>
--	--

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>it can cause a lot of negative side effects, specifically around mood.</p> <p>Citalopram is another antianxiety/antidepressant. It's an SSRI. We start at 10 mg at bedtime. And similar to the venlafaxine, you can increase it every 2 to 4 weeks. Max dose is 40 mg. It does interact with tamoxifen, so it cannot be taken with that medication. But it does not interact with the aromatase inhibitors.</p> <p>And finally, oxybutynin. This one has been shown to reduce hot flashes by about 70%. So very, very effective. Starting at 2.5 mg twice a day, and then you can increase it as needed after the first 2 weeks for a max dose of 5 mg twice daily. It does cause some dry mouth, so I have patients often discontinue it. However, it works so well. So it's always in my back pocket if these first 3 don't work.</p>
--	--	--

<p>24</p>	 <p>Vaginal Dryness: Interventions</p> <p>Nonpharmacologic</p> <ul style="list-style-type: none"> Refer to gynecology for examination and recommendations Lubrication during intercourse: water or oil based Daily lubrication at bedtime Taking HT at different time of day doesn't usually help <p>Low-Dose Local Estrogen Therapy</p> <ul style="list-style-type: none"> Estradiol Ring: leave in place x 12 weeks, then remove and replace. Can be hard to place or remove. If very dry, it may be painful to place the first ring. May not stay in place. Can be felt by partner sometimes.¹ Estradiol Vaginal Suppository (4-10 µg): 1 tablet 1-2 times weekly at bedtime. Can be messy. Do not use more often than twice weekly.² Estradiol Cream (0.1 mg/g): tiny rice-sized amount vaginally once weekly. Hard to control dose. Higher absorption systemically.³ Not recommended: for patients receiving AI due to increased risk of breast cancer recurrence.⁴ Testosterone topically results in higher systemic levels of estradiol and should not be used. <p><small>1. Estradiol vaginal ring PI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020472/020709.pdf 2. Estradiol vaginal inserts PI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020594/020219.pdf 3. Estradiol vaginal cream PI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/060600/0109.pdf 4. SOSTER, et al. https://doi.org/10.1093/jco/17.12.2771</small></p>	<p>Vaginal dryness is a very common side effect with the aromatase inhibitors. I don't see it as much with tamoxifen. We have, again, nonpharmacologic solutions.</p> <p>One is, I make sure that they're tied in with gynecology because the gynecologist often has really great ideas and ways of improving vaginal dryness. They also can actually do the pelvic exam and make sure there's nothing else going on.</p> <p>I have patients lubricate during intercourse with something that's water- or oil-based. They use coconut oil. They use all those things that are out on the market for water-based lubrications.</p> <p>And I also have patients do a daily lubrication at nighttime. That can really help. And it's best to start that off early on, to prevent the dryness. So it can really help the mucosa stay nice and plump. One example is taking a vitamin E tablet and</p>
-----------	---	---


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

	<p>breaking it a little bit and then placing that vaginally at bedtime, but wearing a panty liner. Or putting some coconut oil vaginally. You can make little ice cubes of that, but using a panty liner as well because it can get a little messy.</p> <p>And then, taking the hormone therapy at a different time of day doesn't usually help, but you can always try that.</p> <p>There are some low-dose estrogen therapies that we feel comfortable with. They've been studied in some trials. Not all of these have been studied yet. And they haven't been shown to increase serum estradiol levels by much.</p> <p>So the estradiol ring. This one has been studied. This is a ring that contains a low dose of estrogen. It's placed vaginally. It's left in place for 12 weeks and then removed. And then you replace it.</p> <p>Some issues with that are it can be hard to remove or place. It's a very stiff ring. If you already have vaginal dryness, placing it that first time can really be very difficult, so you have to use a lot of lubrication. Once you start using it, the mucosa is nice and plump and it usually is not an issue after that; it's just that first placement. Sometimes the gynecologist can place it for the patient in the beginning.</p> <p>The partner can sometimes feel it during intercourse, so patients sometimes want to remove it—just so that they know they can do that and put it back in. They don't have to get a new ring.</p> <p>The estradiol vaginal suppositories are very useful. You can use them 1 or 2 times weekly. Patients without breast cancer are using those daily. We do not do that with breast cancer. They wear a panty liner. They do it at bedtime.</p>
--	---


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>There's also estradiol cream. This is my least favorite one because it's really hard to monitor how much the patient's using. But they can use a rice-sized amount vaginally 1 to 2 times a week, similar to the suppository. And that one may have a higher absorption systemically, so I try to avoid that one. However, if that's the only one that works for a patient, I let them use it; I can monitor their estradiol, their serum estradiol if I want, like every 2 weeks, every month, just to make sure that they're not having a lot of updates as well. So that can reassure patients.</p> <p>We don't recommend topicals like testosterone. They definitely increase serum estradiol by quite a bit. So we don't recommend that.</p>
<p>25</p>		<p>So vaginal bleeding on tamoxifen can be a normal period. But we need to determine if it's abnormal bleeding if a patient is telling you that. Some of these patients have had chemotherapy recently, and so their periods stopped. Then they do their radiation or whatever comes next, and then you put them on their tamoxifen and they start having their periods again. So how do you know if that's abnormal vaginal bleeding versus normal vaginal periods?</p> <p>So we can do a laboratory test with the estradiol test to see if their ovaries have turned back on. So if it's elevated, then you know that their ovaries have turned back on and this is a normal period. If it's not, then you start to wonder, is this something else?</p> <p>So then you can get a pelvic ultrasound that can look for thickening of the endometrial lining; that would indicate possible hyperplasia or risk for endometrial cancer. Or you can see if they</p>


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>have a polyp or a fibroid that's enlarged because of the tamoxifen that could itself be bleeding.</p> <p>The important thing is to have them tied in with gynecology at the start of taking their tamoxifen. So you're referring them back to their gynecologist when there's abnormal bleeding. And then the gynecologist can do that biopsy.</p> <p>And then, if the biopsy's negative—say, they find a polyp, they remove the polyp or they do an ablation, and the patient stops bleeding, they can actually continue the tamoxifen. As long as there's no endometrial cancer, it's fine to take tamoxifen if the bleeding item is removed.</p>
<p>26</p>	 <p>Arthralgia: Interventions</p> <p>Exercise¹</p> <ul style="list-style-type: none"> 30 minutes per day, 5 days per week of moderate intensity cardiovascular exercise (walking, biking, swimming, or running) 2 days per week of weight resistance exercise (yoga, Pilates, weightlifting, etc.) <p>Medication</p> <p>NSAIDs: ibuprofen or naproxen as needed. Careful attention to dosing is needed. Can cause gastritis, gastrointestinal bleeding, and reduced kidney function.</p> <p>SNRI: desvenlafaxine-ER²: starting dose 20 mg daily at bedtime. Must take every day. Increase dose every 2-4 weeks by 20 mg (max dose 60 mg). Can cause dizziness, nausea, and fatigue for the first week.</p> <p><small>¹Not US Food and Drug Administration approved for arthralgia. ²ER: extended-release; NSAID: nonsteroidal anti-inflammatory drug; SNRI: serotonin-norepinephrine reuptake inhibitor. 1. Iwan WL, et al. J Clin Oncol. 2016;34:1104-1111.</small></p>	<p>So for arthralgia, this is super common in patients taking aromatase inhibitors. Like I said earlier, some trials found it to be 40% of patients, others 50%. Very, very common.</p> <p>We know that these joint aches and stiffness are likely going to occur in our patients. What we have found, there was a trial called the HOPE trial, where they looked at exercise and they measured how much exercise the patients were doing and they found that quite a bit of exercise was needed to reduce patients' experience of arthralgia.</p> <p>So it was 30 minutes a day, 5 days a week, of moderate intensity cardiovascular exercise, like walking, biking, swimming, or running. And 2 days a week of something with weight resistance, like yoga, Pilates, or literal weightlifting. There are many other options. But all of this is what they found to reduce the experience of arthralgia.</p> <p>So this seems like a lot. I tell patients to start slow if they're not doing anything. Do</p>


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>it 1 or 2 days a week. And then slowly have a goal of building up. I also tell them, exercise by itself has shown to reduce the risk of breast cancer, and so that really motivates them.</p> <p>It also keeps their heart healthy, which is something that we maybe as a breast cancer nurse I don't think about a lot, but it's something that patients should be thinking about. It is one of the leading killers in the United States.</p> <p>Medications can help with arthralgias. I tend to try to avoid them and start with exercise as the mainstay of therapy. But you can have patients take ibuprofen or naproxen as needed. We need to make sure they're taking that with food. And we need to make sure that it's not affecting their kidneys negatively.</p> <p>And then there is one SNRI that's actually been shown to reduce joint aches and stiffness for patients on aromatase inhibitors specifically, and that's desvenlafaxine. I start patients at 20 mg a day and slowly, over 2 to 4 weeks, can ramp up. The max dose is 60 mg. It can cause dizziness, nausea, and fatigue that first week, but if they can get through that, usually those symptoms get better.</p>
<p>27</p>	 <p>Osteoporosis: Interventions</p> <ul style="list-style-type: none"> Check bone density every 1-2 years while on AIs or ovarian suppression If osteopenia, consider bone-modifying therapy; encourage weight-bearing exercise, calcium and vitamin D supplementation If osteoporosis, start bone-modifying therapy; encourage weight-bearing exercise, calcium and vitamin D supplementation <p><small>Stratton J, et al. J Gen Int Pract. 2017;13:e005-e015. Strickland D, et al. J Clin Endocrinol Metab. 2005;105:spaa048. Shapiro CL. Breast Cancer Manag. 2002;9: 60-10. 23173916-0203-0012.</small></p>	<p>Osteoporosis: For patients getting aromatase inhibitors, osteoporosis is a concern. We check the bone density every 1 to 2 years while they're on the aromatase inhibitor, or ovarian suppression, actually, because that can reduce their estrogen and therefore increase the risk of decreased bone density.</p> <p>If they have osteopenia and they're on this aromatase inhibitor, we consider a bone-modifying therapy. Encourage weight-bearing exercise. That's any exercise,</p>





Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>except for swimming, that's been shown to improve bone density—so anything really that requires gravity; walking is weight-bearing.</p> <p>Calcium with vitamin D supplementation can be very helpful as well. We check vitamin D levels as well, just to make sure we don't need to give them extra vitamin D.</p> <p>If they have osteoporosis, we definitely will start bone-modifying therapy and encourage weight-bearing exercise, as well as the calcium and vitamin D. The medications that we use for increasing bone density (the bone-modifying therapy) is zoledronic acid; that's given every 6 months, for a maximum of 5 years.</p> <p>So my feeling about osteoporosis and osteopenia in patients taking aromatase inhibitors is that it's something that we should be watching. It is a negative effect of our therapy. But their rates of fracture were not that high in the studies. And so, I try to reassure patients that I'm not worried about them fracturing, unless they're somebody that falls a lot or somebody that's doing some contact sport. But generally, that's not most of my patients.</p>
28		So now we'll talk about side effects of abemaciclib.



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

<p>29</p>	 <p>Interactive Question</p> <p>Which of the following is a common adverse event (≥20%) in patients receiving adjuvant ET + abemaciclib for early breast cancer?</p> <ul style="list-style-type: none"> a. Rash b. Diarrhea c. Pneumonitis d. Hot flashes e. I'm not sure 	<p>So which of the following is a common adverse event in 20% or more patients receiving adjuvant endocrine therapy and abemaciclib for early breast cancer?</p> <ul style="list-style-type: none"> a) Rash b) Diarrhea c) Pneumonitis d) Hot flashes e) I'm not sure 																																																			
<p>30</p>	 <p>Interactive Question</p> <p>Which of the following is a common adverse event (≥20%) in patients receiving adjuvant ET + abemaciclib for early breast cancer?</p> <ul style="list-style-type: none"> a. Rash b. Diarrhea c. Pneumonitis d. Hot flashes e. I'm not sure <p><small>Pain H, et al. N Engl J Med. 2017;377:1836-1846.</small></p>	<p>The answer here is diarrhea. We do see rash, although rare, with abemaciclib. Pneumonitis is rare as well, something to be monitoring; we'll talk about that more. And hot flashes, you would see those with any patient on endocrine therapy; it wouldn't be specific to the abemaciclib.</p>																																																			
<p>31</p>	 <p>Ellie: Case Continued</p> <ul style="list-style-type: none"> ▪ Ellie starts adjuvant letrozole plus abemaciclib ▪ She has laboratory testing with CBC/differential and comprehensive metabolic panel (electrolytes, creatinine, and LFTs) 2 weeks post-treatment initiation ▪ Also at 2 weeks post-treatment initiation, Ellie develops grade 2 diarrhea <p>What would be the next appropriate step for managing this patient?</p> <p><small>LFT: liver function test.</small></p>	<p>So we're going to talk about Ellie again. She starts adjuvant letrozole and the abemaciclib. She has laboratory testing 2 weeks after with CBC/differential and a comprehensive metabolic panel. That panel includes electrolytes, creatinine, and liver function tests.</p> <p>She also, at 2 weeks post-treatment initiation, tells you that she's had some diarrhea. It's been grade 2, meaning 4 to 6 episodes in a 24-hour period.</p> <p>What would be the appropriate next step for managing her?</p>																																																			
<p>32</p>	 <p>Toxicities: Abemaciclib + NSAIs</p> <table border="1"> <thead> <tr> <th rowspan="2">AEs, %</th> <th colspan="3">MONARCH-3 Abemaciclib + NSA1 (n=327)</th> </tr> <tr> <th>Any Grade</th> <th>Grade 3</th> <th>Grade 4</th> </tr> </thead> <tbody> <tr> <td>Neutropenia</td> <td>41.3</td> <td>19.6</td> <td>1.5</td> </tr> <tr> <td>Gastrointestinal</td> <td></td> <td></td> <td></td> </tr> <tr> <td> Diarrhea</td> <td>81.3</td> <td>9.5</td> <td>0</td> </tr> <tr> <td> Vomiting</td> <td>26.4</td> <td>1.2</td> <td>0</td> </tr> <tr> <td> Abdominal pain</td> <td>28.1</td> <td>1.2</td> <td>-</td> </tr> <tr> <td> Decreased appetite</td> <td>24.5</td> <td>1.2</td> <td>0</td> </tr> <tr> <td>LFTs</td> <td></td> <td></td> <td></td> </tr> <tr> <td> Increased ALT</td> <td>15.6</td> <td>5.8</td> <td>0.3</td> </tr> <tr> <td> Increased AST</td> <td>15</td> <td>3</td> <td>0</td> </tr> <tr> <td> Increased ALT, AST, and/or blood bilirubin</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Fatigue</td> <td>40.1</td> <td>1.8</td> <td>-</td> </tr> </tbody> </table> <p><small>No grade events for this adverse event. ALT: alanine aminotransferase; AST: aspartate aminotransferase; NSA1: nonsteroidal AI. Source: MPF et al. JCO. 2017;35:3628-3636.</small></p>	AEs, %	MONARCH-3 Abemaciclib + NSA1 (n=327)			Any Grade	Grade 3	Grade 4	Neutropenia	41.3	19.6	1.5	Gastrointestinal				Diarrhea	81.3	9.5	0	Vomiting	26.4	1.2	0	Abdominal pain	28.1	1.2	-	Decreased appetite	24.5	1.2	0	LFTs				Increased ALT	15.6	5.8	0.3	Increased AST	15	3	0	Increased ALT, AST, and/or blood bilirubin	-	-	-	Fatigue	40.1	1.8	-	<p>So let's just go over the MONARCH-3 trial adverse events that were reported. They found that 40% of patients experience neutropenia; about half of those had grade 3 or grade 4 neutropenia.</p> <p>GI side effects: Most common was diarrhea and that was occurring in 80% of patients. Only 10% had grade 3 diarrhea, so that would be 7 or 8 stools in a 24-hour period. But there was diarrhea in most patients.</p>
AEs, %	MONARCH-3 Abemaciclib + NSA1 (n=327)																																																				
	Any Grade	Grade 3	Grade 4																																																		
Neutropenia	41.3	19.6	1.5																																																		
Gastrointestinal																																																					
Diarrhea	81.3	9.5	0																																																		
Vomiting	26.4	1.2	0																																																		
Abdominal pain	28.1	1.2	-																																																		
Decreased appetite	24.5	1.2	0																																																		
LFTs																																																					
Increased ALT	15.6	5.8	0.3																																																		
Increased AST	15	3	0																																																		
Increased ALT, AST, and/or blood bilirubin	-	-	-																																																		
Fatigue	40.1	1.8	-																																																		



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>Liver function test abnormalities occurred in about 15% of patients. A low portion of those experienced grade 3 or grade 4 liver function abnormalities. It's usually the ALT and AST.</p> <p>And fatigue was experienced in 40% of patients.</p>										
<p>33</p>	 <p>Abemaciclib: CDK4/6 AE Monitoring</p> <p>Monitor CBC:</p> <ul style="list-style-type: none"> Before starting therapy Every 2 weeks for the first 2 cycles Monthly for the next 2 months When clinically indicated <p><small>Abemaciclib PI: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/141050Orig1s000.pdf</small></p>	<p>So before starting therapy, every 2 weeks for the first 2 cycles, and then monthly, the CBC/differential should be monitored. And then also when clinically indicated.</p>										
<p>34</p>	 <p>Abemaciclib: Monitoring and Managing Neutropenia</p> <p>CBC Monitoring:</p> <ul style="list-style-type: none"> At baseline Cycles 1 and 2 <ul style="list-style-type: none"> Every 2 weeks Cycles 3-6 <ul style="list-style-type: none"> At the beginning of each cycle and as clinically indicated <table border="1" data-bbox="565 951 870 1125"> <thead> <tr> <th>CTCAE Grade</th> <th>Dose Modifications</th> </tr> </thead> <tbody> <tr> <td>1 or 2: ANC 1000/mm³ to <LLN</td> <td>No dose modification required</td> </tr> <tr> <td>3: ANC 500 to <1,000/mm³</td> <td>Suspend dose until toxicity resolves to grade <2; no dose reduction required. If toxicity recurs at grade 3, dose interruption until recovery, then resume at the next lower dose level.</td> </tr> <tr> <td>3 febrile neutropenia*: ANC 500 to <1,000/mm³</td> <td>Suspend dose until toxicity resolves to grade <2; resume at next lower dose.</td> </tr> <tr> <td>4: ANC <500/mm³</td> <td>Suspend dose until toxicity resolves to grade <2; resume at next lower dose.</td> </tr> </tbody> </table> <p><small>*Grade 3 neutropenia with single episode of fever >38.3 °C (101.3 °F) for >1 hour and/or concurrent infection. ANC, absolute neutrophil count; CTCAE, Common Terminology Criteria for Adverse Events; LLN, lower limit of normal. Abemaciclib PI: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/141050Orig1s000.pdf</small></p>	CTCAE Grade	Dose Modifications	1 or 2: ANC 1000/mm ³ to <LLN	No dose modification required	3: ANC 500 to <1,000/mm ³	Suspend dose until toxicity resolves to grade <2; no dose reduction required. If toxicity recurs at grade 3, dose interruption until recovery, then resume at the next lower dose level.	3 febrile neutropenia*: ANC 500 to <1,000/mm ³	Suspend dose until toxicity resolves to grade <2; resume at next lower dose.	4: ANC <500/mm ³	Suspend dose until toxicity resolves to grade <2; resume at next lower dose.	<p>So when monitoring the CBC, you're looking at the absolute neutrophil count. If it's greater than 1000/mm³, you just continue at the current dose; you don't have to change anything.</p> <p>If a patient experiences ANC at 500 to 1000/mm³, you would hold the medication, the abemaciclib. Continue the endocrine therapy. Wait for their neutrophil count to rise above 1000/mm³. And then resume at the previous dose.</p> <p>However, if that happens again, next time you get labs, they're down below 1000/mm³ but above 500/mm³, you then hold the medication, wait till they get to be above 1000/mm³, but then you resume at the next lower dose level. And we'll talk about the dose levels a little bit later in the talk.</p> <p>If they have febrile neutropenia, which was rare in this trial, but it did occur, and they have this ANC that's below 1000/mm³ but above 500/mm³, you would stop the medication, wait till they recovered, wait till their infection, if they experience that,</p>
CTCAE Grade	Dose Modifications											
1 or 2: ANC 1000/mm ³ to <LLN	No dose modification required											
3: ANC 500 to <1,000/mm ³	Suspend dose until toxicity resolves to grade <2; no dose reduction required. If toxicity recurs at grade 3, dose interruption until recovery, then resume at the next lower dose level.											
3 febrile neutropenia*: ANC 500 to <1,000/mm ³	Suspend dose until toxicity resolves to grade <2; resume at next lower dose.											
4: ANC <500/mm ³	Suspend dose until toxicity resolves to grade <2; resume at next lower dose.											


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>is resolved, and then resume at the lower dose.</p> <p>And if they have an ANC of less than 500/mm³, you would wait, stop the drug. Wait till they get above 1000/mm³ and then resume at the next lower dose.</p>																		
<p>35</p>	 <p>Course of Abemaciclib-Induced Diarrhea</p> <p>MONARCH-2 MONARCH-3</p> <p>Number of Patients</p> <p>Cycles</p> <p>■ Represents those with grade 2 diarrhea or grade 3 neutropenia</p> <p>The median duration of diarrhea was 9-12 days for grade 2 events and ranged from 6-8 days for grade 3 events</p> <p>Rugg HS, et al. <i>Oncologist</i>. 2021;26:e633-e635.</p>	<p>For diarrhea, what they found was that it was higher during the first cycle. It usually occurs pretty quickly after patients start treatment, after a week or so. And what they found was that, as cycles went on, the diarrhea got better, in both the MONARCH-2 and the MONARCH-3 trial.</p> <p>And whether that's because the toxicity actually decreases with the drug or because patients become a little bit better at taking loperamide—sometimes they're taking it preventively, like a half tablet of loperamide every day, or they're taking it more quickly, as soon as the diarrhea occurs—it's unclear if this is just better management or decreased toxicity over time.</p> <p>If patients experience diarrhea for grade 2 events, it usually lasted 9 to 12 days; if it was grade 3, 6 to 8 days in the trials.</p>																		
<p>36</p>	 <p>Abemaciclib: Management of Treatment-Induced Diarrhea</p> <p>At the first sign of loose stools, start antidiarrheal agents (eg, loperamide) and increase intake of oral fluids</p> <table border="1"> <thead> <tr> <th>GRADE 1</th> <th>GRADE 2</th> <th>GRADE 3</th> <th>GRADE 4</th> </tr> </thead> <tbody> <tr> <td>Increase of 4+ stools per day over baseline</td> <td>Increase of 4-8 stools per day over baseline</td> <td>Increase of ≥23 stools per day over baseline</td> <td>Life-threatening consequences/urgent intervention indicated</td> </tr> <tr> <td>No dose modification required</td> <td>Not resolved to grade 1 within 24 hours</td> <td rowspan="2">Suspend dose until toxicity resolves to grade 1</td> <td rowspan="2">Dose must be reduced</td> </tr> <tr> <td></td> <td>Persistent or recurrent</td> </tr> <tr> <td></td> <td>Dose must be reduced in case of persistent or recurrent grade 2</td> <td></td> <td></td> </tr> </tbody> </table> <p>A dose reduction corresponds to a reduction of 50 mg of abemaciclib at a time; discontinue abemaciclib for patients unable to tolerate 50 mg twice daily</p> <p>Rugg HS, et al. <i>Oncologist</i>. 2021;26:e633-e635. Abemaciclib PI. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/141051Orig1s010/Abemaciclib_PI.pdf</p>	GRADE 1	GRADE 2	GRADE 3	GRADE 4	Increase of 4+ stools per day over baseline	Increase of 4-8 stools per day over baseline	Increase of ≥23 stools per day over baseline	Life-threatening consequences/urgent intervention indicated	No dose modification required	Not resolved to grade 1 within 24 hours	Suspend dose until toxicity resolves to grade 1	Dose must be reduced		Persistent or recurrent		Dose must be reduced in case of persistent or recurrent grade 2			<p>So how do we manage this? At the first sign of loose stools, we have patients start their antidiarrheal agents, like loperamide, as I discussed previously, and increase their oral fluid intake.</p> <p>I also, just in addition to that, have them change their diet to more of a BRAT diet, those bland foods, avoid spicy things, avoid a lot of acidic foods. That can help a lot.</p> <p>So if they're experiencing grade 1 diarrhea, no more than 4 stools a day, they can just continue the medication and take their loperamide.</p>
GRADE 1	GRADE 2	GRADE 3	GRADE 4																	
Increase of 4+ stools per day over baseline	Increase of 4-8 stools per day over baseline	Increase of ≥23 stools per day over baseline	Life-threatening consequences/urgent intervention indicated																	
No dose modification required	Not resolved to grade 1 within 24 hours	Suspend dose until toxicity resolves to grade 1	Dose must be reduced																	
	Persistent or recurrent																			
	Dose must be reduced in case of persistent or recurrent grade 2																			



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>But if they are, like Ellie, who is having grade 2 diarrhea, she had 4 to 6 stools per day over her baseline, you would stop the medication, wait till she has less than 4 stools a day. We'd be starting her on loperamide to get to that point. And then, you could resume at the previous dose.</p> <p>However, if you resume at the previous dose and she again goes right back to having 4 to 6 stools per day, then you'd want to stop the medication, wait till she has less than 4 stools a day, and then go to the next lower dose level.</p> <p>If the patients have grade 3 or grade 4 diarrhea, 7 stools a day or more, you would stop the medication. Wait till their diarrhea reduces to less than 4 a day, and then you would reduce the dose.</p> <p>So the dose reductions, like I said, we'll be discussing in a later slide.</p>										
<p>37</p>	 <p>Abemaciclib: Monitoring and Managing Hepatotoxicity</p> <ul style="list-style-type: none"> Elevations in serum transaminase levels have been observed with abemaciclib Perform LFTs before treatment initiation and inform patients of the signs and symptoms of hepatotoxicity Monitor LFTs every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated thereafter <table border="1"> <thead> <tr> <th>CTCAE Grade for ALT and AST</th> <th>Abemaciclib Dose Modifications</th> </tr> </thead> <tbody> <tr> <td>Grade 1 (>ULN 3.0 x ULN) grade 2 (>3.0-5.0 x ULN), without increase in total bilirubin >2 x ULN</td> <td>No dose modification required</td> </tr> <tr> <td>Persistent or recurrent grade 2, or grade 3 (>5.0-20.0 x ULN), without increase in total bilirubin >2 x ULN</td> <td>Suspend dose until toxicity resolves to baseline or grade 1 Resume at next lower dose</td> </tr> <tr> <td>Elevation in AST and/or ALT >3 x ULN with total bilirubin >2 x ULN, in the absence of cholestasis</td> <td>Discontinue abemaciclib</td> </tr> <tr> <td>Grade 4 (>20.0 x ULN)</td> <td>Discontinue abemaciclib</td> </tr> </tbody> </table> <p><small>ULN, upper limit of normal Abemaciclib (E) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021129Orig1s000a07700980.pdf</small></p>	CTCAE Grade for ALT and AST	Abemaciclib Dose Modifications	Grade 1 (>ULN 3.0 x ULN) grade 2 (>3.0-5.0 x ULN), without increase in total bilirubin >2 x ULN	No dose modification required	Persistent or recurrent grade 2, or grade 3 (>5.0-20.0 x ULN), without increase in total bilirubin >2 x ULN	Suspend dose until toxicity resolves to baseline or grade 1 Resume at next lower dose	Elevation in AST and/or ALT >3 x ULN with total bilirubin >2 x ULN, in the absence of cholestasis	Discontinue abemaciclib	Grade 4 (>20.0 x ULN)	Discontinue abemaciclib	<p>The elevations in the transaminases were seen in patients taking abemaciclib. So we do this comprehensive metabolic panel, and we check their LFTs every 2 weeks for the first 2 months, and then every month after that.</p> <p>Patients that had a rise in their LFTs that was greater than 3 times the upper limit of normal, but they had a total bilirubin that remains no greater than 2 times the upper limit of normal, you could continue the medication.</p> <p>However, if their LFTs rise even further, although the total bilirubin is still doing okay, you could just stop the medication, wait till they have a reduction in their LFTs and then resume at the next lower dose.</p> <p>If they're having a rise in their AST and ALT, as well as their total bilirubin, they can no</p>
CTCAE Grade for ALT and AST	Abemaciclib Dose Modifications											
Grade 1 (>ULN 3.0 x ULN) grade 2 (>3.0-5.0 x ULN), without increase in total bilirubin >2 x ULN	No dose modification required											
Persistent or recurrent grade 2, or grade 3 (>5.0-20.0 x ULN), without increase in total bilirubin >2 x ULN	Suspend dose until toxicity resolves to baseline or grade 1 Resume at next lower dose											
Elevation in AST and/or ALT >3 x ULN with total bilirubin >2 x ULN, in the absence of cholestasis	Discontinue abemaciclib											
Grade 4 (>20.0 x ULN)	Discontinue abemaciclib											



Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>longer be taking the medication; you have to stop the abemaciclib.</p> <p>And if they're having grade 4, obviously, no more abemaciclib.</p>
<p>38</p>	 <p>Abemaciclib: Monitoring and Managing Venous Thromboembolism</p> <ul style="list-style-type: none"> Monitor patients for signs and symptoms of thrombosis and PE For venous thromboembolism of any grade, suspend dose and treat as clinically indicated; resume when the patient is clinically stable Advise patients to immediately report any signs or symptoms of thromboembolism such as pain or swelling in an extremity, shortness of breath, chest pain, tachypnea, and tachycardia <p><small>HCP: Healthcare provider. ILD: Interstitial lung disease. Abemaciclib PI: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020971s01/000007/000001.pdf</small></p>	<p>So venous thromboembolism was seen in low rates, but it was seen in the trials. So deep vein thrombosis or pulmonary embolism. So what we do is we talk to the patients about what to look for, and we work it out pretty quickly if they have shortness of breath, chest pain, swelling in 1 leg. We stop the medication. We treat the clot, and then once the symptoms are better, shortness of breath or chest pain or leg swelling, we can resume the abemaciclib at the previous dose.</p> <p>But if that happens again, of course, we're not going to be continuing the medication. Usually it doesn't because they're on a blood thinner at that point.</p>
<p>39</p>	 <p>Abemaciclib: Risk of ILD or Pneumonitis</p> <ul style="list-style-type: none"> Any-grade ILD or pneumonitis noted in 3% of all patients Grade 3 or 4 events occurred in 0.1% to 0.6% of patients in trials Patients should be counseled on importance of contacting their HCP in case of dry cough with/without fever or shortness of breath Monitor regularly for pulmonary symptoms indicative of ILD or pneumonitis (eg, hypoxia, cough, or dyspnea) Interrupt or dose-reduce therapy for persistent or recurrent grade 2 ILD/pneumonitis Permanently discontinue if recurrent or severe ILD/pneumonitis (grade ≥3) <p><small>HCP: Healthcare provider. ILD: Interstitial lung disease. Abemaciclib PI: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020971s01/000007/000001.pdf</small></p>	<p>ILD or pneumonitis was seen in patients taking abemaciclib at only 3%. But it's something that we should be careful of because the grade 3 or 4 events did occur in the trial; at small rates, but these are deadly situations. So we make sure that we monitor for this and catch it quickly.</p> <p>So we counsel patients. We tell them what to look for— shortness of breath and cough. They need to tell us that between visits. Every time they come in, we ask them about those symptoms again. And then if we do think that they might be having an experience of pneumonitis or ILD, we have them stop the medication right away. We work them up for it. We get the chest CT.</p> <p>And then if they do have pneumonitis, we treat them with steroids. Sometimes we can, again, try, if it's a mild case of pneumonitis or if it's mostly</p>


Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>asymptomatic, we can put them back on the abemaciclib again. However, if it recurs, or if they have a lot of symptoms, we would not be able to continue the abemaciclib anymore.</p>								
40	 <p>Abemaciclib: Dose Modifications</p> <table border="1"> <thead> <tr> <th>Dose Level</th> <th>Abemaciclib</th> </tr> </thead> <tbody> <tr> <td>Recommended starting dose in combination with fulvestrant, tamoxifen, or an AI</td> <td>150 mg twice daily</td> </tr> <tr> <td>First dose reduction</td> <td>100 mg twice daily</td> </tr> <tr> <td>Second dose reduction</td> <td>50 mg twice daily</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Medication should be taken at approximately the same time each day Avoid concomitant use of strong and moderate CYP3A4 inhibitors and inducers <p><small>Abemaciclib-PI: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/150065/071/0081.pdf</small></p>	Dose Level	Abemaciclib	Recommended starting dose in combination with fulvestrant, tamoxifen, or an AI	150 mg twice daily	First dose reduction	100 mg twice daily	Second dose reduction	50 mg twice daily	<p>For the dose modifications, I keep referring to this slide and here we are. A starting dose is 150 mg twice daily. There are pills out there for taking 200 mg twice daily, but that is for monotherapy without endocrine therapy, so make sure that your patients are not getting that dose. It's 150 mg twice daily.</p> <p>And the first dose reduction is 100 mg twice daily. And the next dose reduction is 50 mg twice daily. And after that, you discontinue the medication because it's no longer thought to be efficacious at doses lower than 50 mg twice a day.</p> <p>It also should be avoided with strong and moderate CYP3A4 inhibitors. So having the pharmacist really help you with looking at the medications for each patient and adjusting those medications so the patient is not experiencing more toxicity from the abemaciclib or reduced efficacy of the abemaciclib.</p>
Dose Level	Abemaciclib									
Recommended starting dose in combination with fulvestrant, tamoxifen, or an AI	150 mg twice daily									
First dose reduction	100 mg twice daily									
Second dose reduction	50 mg twice daily									
41	 <p>Key Takeaways</p> <ul style="list-style-type: none"> Data on the optimal timing of adjuvant ET are emerging and suggest that treatment extension for up to 10 years may further reduce recurrence and improve benefit compared with 5 years Treatment should be individualized and consider underlying risk and short-/long-term side effects AEs are an important cause of nonadherence to long-term adjuvant therapy in EBC, although most are manageable Oncology nurses can promote treatment adherence by addressing treatment-related AEs and delivering appropriate patient education and counseling 	<p>So key takeaways:</p> <p>Data on the optimal timing of adjuvant endocrine therapy, 5 versus 10 years, are emerging. And we may further be able to decide which patients would benefit with a longer duration of endocrine therapy. The Breast Cancer Index is certainly hopeful.</p> <p>Treatment should be individualized, and we should be considering the underlying risks, the short- and long-term side effects for each patient.</p>								

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

Adverse Event Management of Oral Therapies in HR+/HER2- EBC

		<p>Adverse events are an important cause of nonadherence to long-term adjuvant therapy in early-stage breast cancer. But most of these side effects can be managed.</p> <p>And it is our job as oncology nurses to promote treatment adherence by addressing treatment-related adverse events and delivering appropriate patient educate and counseling.</p>
42		Thank you very much for joining me today.